RAW_covid500_LM_RW_def.csv

Five hundred patients with COVID-19 confirmed by RT-PCR in nasopharyngeal exudate were included in the study. These patients required ICU, internal medicine or pulmonology hospitalization in the Hospital Clinic o Barcelona between March and June 2020. The clinical and laboratory data that we collected in our database were the first available information of the patient within the 48 hours after admission. The variables included were: age, sex, smoking and drinking habits, asthma, chronic obstructive pulmonary disease (COPD), diabetes mellitus, dyslipidemia, obesity, hypertension, heart failure, ischemic heart disease, hospitalization days, intensive care unit stay, and in-hospital death. <br>Blood samples were collected into lithium heparin- , EDTA and citrate-coated blood collection tubes for biochemical, hematological and coagulation testing, respectively. Alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), creatinine (CREA), ferritin (FER), gamma-glutamyl transpeptidase (GGT), glucose (GLU), lactate dehydrogenase (LDH), C-reactive protein (CRP), procalcitonin (PCT), and troponin I (TNI), were measured using an Atellica automated analyzer (Siemens Healthineers, Tarrytown, NY, USA). Hematological parameters (including hemoglobin (HB) and platelets (PLT), leukocytes (LEU), lymphocytes (LYMP), and neutrophils (NEU) count), were analyzed using an Advia 2120 (Siemens Healthineers, Tarrytown, NY, USA). Finally, the Sysmex 5100 (Sysmex, Kobe, Japan) was used for d-dimer (DD), prothrombin time (PT) and partial thromboplastin time (PTT) analysis.